WO2013161408A1

WO2013161408A1 - Method for inducing t cell differentiation, method for producing t cells, t cells, pharmaceutical composition, and screening method

Info

Publication number: WO2013161408A1
Application number: PCT/JP2013/056758
Authority: WO
Inventors: 菅井学; 清水章; 南部由希子
Original assignee: 国立大学法人京都大学
Priority date: 2012-04-26
Filing date: 2013-03-12
Publication date: 2013-10-31
Also published as: JPWO2013161408A1; JP5900865B2

Abstract

Provided is a method for inducing differentiation of CD4-CD8αα+ T cells. One or multiple embodiments pertain to a method for inducing differentiation of CD4-CD8αα+ T cells from CD4+CD8-T cells, the method comprising in vitro cultivation of CD4+CD8- T cells under conditions wherein IL-2, TGF-β1, and atRA are present.

Description

T cell differentiation induction method, T cell production method, T cell, pharmaceutical composition, and screening method

The present disclosure relates to a T cell differentiation induction method, a T cell production method, a T cell, a pharmaceutical composition, and a screening method.

It is most important in controlling the acquired immune response to correctly select whether to induce an immune response or induce immune tolerance against a specific antigen. Tolerance to self-antigens is regulatory T cells (nTreg) produced in the thymus, and inducible regulatory T cells (iTreg) are important for suppressing excessive immune responses in the intestine, both of which are CD4 + Foxp3 + 3T cells It is known that For the purpose of treating autoimmune diseases, attempts have been made to use CD4 + Foxp3 + regulatory T cells to suppress excessive immune responses and immune responses to self. Attempts have also been made to suppress CD4 + Foxp3 + regulatory T cells for the purpose of releasing the immunosuppressive state against the tumor and treating the tumor. In addition, it has been reported that iTreg can be induced from naive CD4 細胞 T cells in vitro, and that retinoic acid increases the induction efficiency of iTreg (Non-patent Documents 1 and 2).

On the other hand, it has been reported that CD8 + T cells also have regulatory T cells. CD8αβ + CD122 + CD44 + ICOSL + TCRαβ + T cells are known to attenuate immune responses (Non-patent Document 3). In addition, CD8αα + CD122 + TCRαβ + T cells were identified by screening for regulatory T cells that inhibit experimental autoimmune encephalitis (EAE) (Non-patent Documents 4 and 5). It has been reported that transplantation of CD8αα + TCRαβ + T cells can suppress colitis that occurs when naive CD4 T cells are transplanted into SCID mice (Non-patent Document 6). In addition, non-obese diabetic mice have impaired generation of CD8αα + TCRαβ + T cells, and it has been pointed out that these cell populations have some regulatory role (Non-patent Document 7).

This disclosure provides a method for inducing differentiation of CD4-CD8αα + T cells.

The disclosure provides, in one or more embodiments, from CD4 + CD8- T cells comprising in vitro culture of CD4 + CD8- T cells in the presence of IL-2, TGF-β1, and atRA. The present invention relates to a method for inducing differentiation of CD4-CD8αα + T cells.

This disclosure relates to CD4-CD8αα + T cells derived from CD4 + CD8-8 T cells, which exist in vitro in one or more embodiments.

The present disclosure relates to a screening method for a substance that promotes or suppresses in vivo differentiation induction from CD4 + CD8- T cells to CD4-CD8αα + T cells in one or a plurality of embodiments.

FIG. 1 shows that in vitro differentiation from naive CD4 ブ T cells to CD4-CD8αα + T cells is promoted by TGF-β1, atRA, and IL-2. FIG. 1a is an example of the result of FACS analysis of naive CD4 T cells stimulated with anti-CD28 antibody, IL-2, TGF-β1, and atRA on a plate coated with anti-CD3ε antibody. FIG. 1b is an example of the result of stimulating CD8αβ + T cells under the same conditions as in FIG. 1a and analyzing differentiation into CD4-CD8αα + T cells by FACS. FIG. 1c is an example of the results of stimulating naive CD4 T cells by combining various ILs with TGF-β1 and atRA and analyzing CD4-CD8αα + T cells by FACS. FIG. 1d is an example of the results of stimulating naive CD4 T cells by combining various concentrations of atRA with TGF-β1 and IL-2 and analyzing CD4-CD8αα + T cells by FACS. Each experiment in FIGS. 1a-d was performed at least 3 times and representative data were shown. FIG. 2 is a diagram confirming gene expression of differentiated CD4-CD8αα + T cells in vitro. FIG. 2a is a diagram showing an example in which naive CD4 T cells were stimulated under the same conditions as in FIG. 1a, and the expression of the indicated genes was evaluated by FACS analysis. FIG. 2b shows that naïve CD4 T cells were stimulated under the same conditions as in FIG. 1a, and CD4 + T cells and CD8 + T cells were selected, and the gene expression in CD4 + T cells, CD8 + T cells, and naive CD4 T cells was RT-PCR. An example of the result analyzed using is shown. Each experiment in FIGS. 2a-b was performed at least 3 times and representative data were shown. FIG. 3 is a view showing CD8αα + T cells in the spleen after immunization. The FACS analysis diagram shows the presence of CD8αα + CD8αβ-CD4-TCRαβ T cells in the spleen after immunization with NP-CGG / alum. The bar graph shows the abundance of CD8αα T cells in CD4-A T cells after immunization and in unimmunized spleen. * P <0.05; N = 3 FIG. 4 is a diagram showing that CD8αα + T cells were generated from CD4 + TCRαβ T cells in Rag2 − / − mice. FACS analysis was performed on lymphocytes of Rag2 − / − mice (CD45.1) 6 months after transplantation of naive CD4 T cells (CD45.2). As lymphocytes, spleen, Peyer's patch (PP), and small intestine and large intestine intraepithelial lymphocytes (IEL) were used. The upper FACS analysis diagram is an example of the results of analyzing the expression of CD4 and CD8α for TCRαβ + CD45.2 + T cells. The middle FACS analysis chart is an example of the results of analyzing the expression of CD8α and CD8β for CD4-CD8 + T cells (I). The lower FACS analysis diagram is an example of the results of analyzing the expression of CD8α and CD8β for CD4 + CD8 + T cells (II). FIG. 5 shows that Runx3 is required for transdifferentiation from naive CD4 ブ T cells to CD4-CD8αα + T cells. It is an example of results obtained by stimulating naive CD4 T cells derived from wild-type or Runx3-/-fetal liver (FL) under the same conditions as in Fig. 1a and analyzing CD4-CD8αααT cells by FACS. Each experiment was performed at least 3 times and representative data were shown. FIG. 6 is a diagram showing that Runx3 is required for CD4-CD8αα + T cells to be generated in vivo from naive CD4 T cells. Rag2-/-mice (CD45.1) transplanted with naive CD4 T cells (CD45.2) obtained from wild-type or Runx3-/-fetal liver (FL) treated with all-trans retinoic acid (atRA) FACS analysis of lymphocytes was performed. As lymphocytes, spleen, Peyer's patch (PP), small intestine and large intestine intraepithelial lymphocytes (IEL), and small intestine and large intestine lamina propria (LPL) were used. Each experiment was performed at least 3 times and representative data were shown. FIG. 7 is a diagram showing that transdifferentiation from CD4 + から T cells to CD4-CD8αα + T cells occurs during the immune response. FIG. 7a shows the expression of CD4 and CD8α for TCRαβ + CD45.2 + T cells from the spleen after injection of naïve CD4 T cells (CD45.2) into Rag2 − / − mice and 1, 3, and 6 days after immunization. Is an example of the result of FACS analysis. FIG. 7b is an example of FACS analysis of lymphocytes obtained from the mouse tissue used in FIG. 7a, and the expression of CD4, CD8α and CD8β in TCRαβ + CD45.2 + T cells was examined. As lymphocytes, Peyer's patch (PP), small intestine and large intestine intraepithelial lymphocytes (IEL), and small intestine and large intestine lamina propria (LPL) were used. Each experiment was performed at least 3 times and representative data were shown. FIG. 8 is a diagram showing that transdifferentiation from CD4 + T cells to CD4-CD8αα + 起こり T cells occurs during an immune response and attenuates the immune response. FIG. 8a shows an example of the results of following up the signs of neurological disease after injecting Rag2-/-mice with wild-type or Runx3-/-lymphocytes and inducing experimental autoimmune encephalitis (EAE). Show. The left graph shows the mean EAE clinical score of 10 mice obtained from two independent experiments, with mean ± standard error. The right graph shows the disease prevalence (%) of 10 mice obtained from two independent experiments. FIG. 8b is a diagram illustrating the differentiation and function of various T cell subsets derived from naive CD4 T cells. Naive CD4 T cells promote immune responses by differentiating into various helper T cells, namely Th1, Th2, Th9, Th17, and TFH cells. Cytotoxic T, B, and other immune responsive cells will be able to participate in the immune response effectively with the help of these CD4 T cells. Strong or long-term inflammation induces TGF-β1 and all-trans retinoic acid (atRA) required for transdifferentiation from CD4 T cells to CD8αα regulatory T cells (CD8ααTreg). Thus, the same two factors induce two regulatory T cell subsets, CD8αα Treg and inducible regulatory T cells (iTreg). As the present disclosure shows, differentiation of CD8αα T cells requires stronger and more continuous stimulation than iTreg. Therefore, the two Tregs may have different immunoregulatory functions. One function of CD8ααTreg is to establish a negative feedback loop in the chronic inflammatory response. That is, it is considered that newly generated CD8αα T cells (α4β7 + CCR9 +) migrate to the intestine and have other functions such as CD8αβ memory cells.

In the present disclosure, when “+” or “-” is not appended to a molecule, it means that the molecule is positive unless otherwise specified. That is, for example, “CD4 T cell” means “CD4 + T cell”.

In the present disclosure, “cell” refers to a human or non-human animal cell unless otherwise specified. The non-human animal is, but is not limited to, a mouse in one or more embodiments.

The following abbreviations may be used in this disclosure.
IL: Interleukin
TGF-β: Transforming growth factor beta
atRA: All-trans retinoic acid or tretinoin
Treg: Regulatory T cells
TCR: T cell receptor
IFN-γ: Interferon gamma
FACS: Fluorescence activated cell sorter (synonymous with flow cytometry)

It is generally considered that T cells are determined to differentiate into three cell lineages of CD8αβ T cells, CD4TT cells, and CD8αα T cells in the thymus, and thereafter there is no change in differentiation in the periphery. Contrary to its general idea, the present disclosure is based on the finding that once differentiated CD4 T cells redifferentiate (transdifferentiate) into CD8αα T cells in the periphery.

[CD4-CD8αα + T cell differentiation induction method]
The disclosure provides, in one or more embodiments, from CD4 + CD8- T cells comprising culturing CD4 + CD8- T cells in vitro under conditions in which IL-2, TGF-β1, and atRA are present. The present invention relates to a method for inducing differentiation of CD4-CD8αα + T cells (hereinafter also referred to as “differentiation induction method according to the present disclosure”).

[CD4 + CD8- T cells]
The CD4 + CD8− T cell is a naive CD4 T cell in one or more embodiments. In the present disclosure, “naive CD4 T cell” refers to a CD4 + T cell that is released to the periphery after immature T cells mature in the thymus and has never been activated by an antigen. The method for obtaining naive CD4 T cells is not particularly limited, and a conventionally known or later developed method for obtaining naive CD4 T cells can be applied. In one or a plurality of embodiments, for example, naive CD4 T cells are obtained by collecting spleen, lymph nodes or peripheral blood of an animal individual, preparing a cell suspension using an appropriate medium or diluent, Examples thereof include a method for isolation from the suspension using a cell-specific surface marker. As a method for separating marker-positive and marker-negative naive T cells, for example, by adding magnetic beads bound with an antibody against the marker to the cell suspension and collecting the magnetic beads with a magnet, the marker is expressed. For example, a method of separating existing T cells (magnetic bead method).

The CD4 + CD8- T cell is an antigen-specific CD4 + CD8- T cell in one or a plurality of embodiments. In one or more embodiments, antigen-specific CD4 + CD8- T cells are collected from the spleen, lymph nodes, or peripheral blood of an immunized animal individual, and a cell suspension is prepared using an appropriate medium or diluent. The method of preparing and isolating from this suspension using a cell-specific surface layer marker is mentioned. Further, in one or a plurality of embodiments, the antigen-specific CD4 + CD8- T cell is isolated from CD4 + CD8- T cells that react with antigen-presenting cells phagocytosed by a specific antigen in vitro, or It can be obtained by, for example, proliferating only antigen-specific CD4 + CD8- T cells in a cell population by antigen-presenting cells phagocytosed with a specific antigen in vitro.

In one or a plurality of embodiments, the number of CD4 + CD8− T cells used for the culture, that is, the number of CD4 + CD8− T cells at the start of the culture is 5.0 × 10 ⁵ cells / mL or less, 3.0 × 10 ⁵ Pieces / mL or less, or 1.0 × 10 ⁵ pieces / mL or less. From the viewpoint of improving the efficiency of inducing differentiation into CD4-CD8αα + T cells, the number of cells at the start of culture is preferably smaller. The lower limit of the number of CD4 + CD8− T cells at the start of the culture is not particularly limited, but in one or more embodiments, 1.0 × 10 ³ in terms of improving the efficiency of inducing differentiation into CD4-CD8αα + T cells. pieces / mL or more, or is 1.0 x 10 ⁴ cells / mL or more.

[Culture plate coated with means to stimulate TCR]
In one or a plurality of embodiments, the culture in the differentiation induction method according to the present disclosure is performed on a culture plate coated with a means for stimulating TCR. By coating the culture plate with a means for stimulating TCR, there is an advantage that the efficiency of inducing differentiation into CD4-CD8αα + T cells can be improved. The means for stimulating TCR is not particularly limited as long as it can stimulate TCR expressed in CD4 + CD8- T cells, and in one or a plurality of embodiments, it is expressed in CD4 + CD8- T cells. It is an antibody against the molecule. The antibody is not particularly limited, and in one or more embodiments, is an anti-CD3 antibody. In one or more embodiments, the anti-CD3 antibody is an anti-CD3ε antibody.

In one or more embodiments, the amount of means for stimulating TCR coated on the culture plate is 0.5 μg / mL or more, 1.0 μg / mL or more, 3.0 μg / mL or more as a value converted to anti-CD3 antibody, Or, it is 5.0 μg / mL or more. From the viewpoint of improving the efficiency of inducing differentiation into CD4-CD8αα + T cells, TCR stimulation is preferably as strong as possible. Therefore, the amount of means for stimulating TCR coated on the culture plate is preferably as large as possible. The upper limit of the amount of the means for stimulating the TCR coated on the culture plate is not particularly limited, and is an extent that does not inhibit differentiation induction into CD4-CD8αα + T cells. In one or a plurality of embodiments, 30 μg / mL It is as follows.

The culture plate coated with a means for stimulating TCR is not particularly limited, and a conventionally known or later developed cell culture plate can be used.

[Culture time]
In one or a plurality of embodiments, the culture time in the differentiation induction method according to the present disclosure is 6 days or more, 7 days or more, 8 days or more, or 9 days or more. From the viewpoint of improving the efficiency of inducing differentiation into CD4-CD8αα + T cells, the culture time is preferably longer than that of iTreg induction. The upper limit of the culture time is not particularly limited and is an extent that does not inhibit differentiation induction into CD4-CD8αα + T cells, and in one or more embodiments, it is 20 days or less.

[AtRA]
In the culture in the differentiation induction method according to the present disclosure, all-trans retinoic acid (atRA) is an essential component. In one or more embodiments, the amount of atRA at the start of the culture is 10 nM or more, 100 nM or more, 1 μM or more, more than 1 μM, 2 μM or more, 5 μM or more, or 10 μM or more. From the viewpoint of improving the efficiency of inducing differentiation into CD4-CD8αα + T cells, the greater the amount of atRA, the better. The upper limit of the abundance of atRN is not particularly limited and is an extent that does not inhibit differentiation induction into CD4-CD8αα + T cells, and in one or more embodiments, is 100 μM or less.

[IL-2]
In the culture in the differentiation induction method according to the present disclosure, IL-2 is an essential component. In one or more embodiments, the amount of IL-2 present at the start of the culture is 10 ng / mL or more, or 15 ng / mL or more. The upper limit of the abundance of IL-2 is not particularly limited, and is an extent that does not inhibit differentiation induction into CD4-CD8αα + T cells, and in one or more embodiments, is 100 ng / mL or less.

[TGF-β1]
In the culture in the differentiation induction method according to the present disclosure, TGF-β1 is an essential component. The abundance of TGF-β1 at the start of the culture is 0.5 ng / mL or more, or 1 ng / mL or more in one or more embodiments. The upper limit of the abundance of TGF-β1 is not particularly limited, and is an extent that does not inhibit differentiation induction into CD4-CD8αα + T cells, and in one or more embodiments, is 50 ng / mL or less.

“Culturing the cells in vitro under conditions where IL-2, TGF-β1, and atRA are present” in one or more non-limiting embodiments, wherein IL-2, TGF-β1, and atRA are This refers to culturing cells in an added culture medium. When the medium is exchanged in the culture in the differentiation induction method according to the present disclosure, a new medium to which IL-2, TGF-β1, and atRA at predetermined concentrations described above are added can be used.

[Other ingredients]
In one or a plurality of embodiments, the culture in the differentiation induction method according to the present disclosure is further performed in the presence of a costimulatory antibody and / or a cytokine blocking antibody. The costimulatory antibody is an anti-CD28 antibody in one or more non-limiting embodiments. In one or more non-limiting embodiments, the cytokine blocking antibody is an anti-IFN-γ antibody and an anti-IL-4 antibody. In one or a plurality of embodiments, the culture in the differentiation induction method according to the present disclosure is one or two or three kinds selected from an anti-CD28 antibody, an anti-IFN-γ antibody, and an anti-IL-4 antibody. Perform in the presence of all antibodies. From the viewpoint of improving the efficiency of inducing differentiation into CD4-CD8αα + T cells, these three types of antibodies (anti-CD28 antibody, anti-IFN-γ antibody, and anti-IL-4 antibody) are preferably present. That is, the culture in the differentiation induction method according to the present disclosure is, in one or a plurality of embodiments, “CD4 + CD8− T cells are IL-2, TGF-β1, atRA, anti-CD28 antibody, anti-IFN-γ antibody, And in vitro culture under conditions where anti-IL-4 antibody is present.

The abundance of the anti-CD28 antibody at the start of the culture is 300 ng / mL or more, or 500 ng / mL or more in one or more embodiments. The upper limit of the abundance of the anti-CD28 antibody is not particularly limited and is an extent that does not inhibit the induction of differentiation into CD4-CD8αα + T cells, and in one or more embodiments, it is 20 μg / mL or less. The abundance of the anti-IFN-γ antibody at the start of the culture is 500 μng / mL or more, or 1 μg / mL or more in one or more embodiments. The upper limit of the abundance of the anti-IFN-γ antibody is not particularly limited, and is an extent that does not inhibit differentiation induction into CD4-CD8αα + T cells, and in one or more embodiments, is 30 μg / mL or less. The abundance of the anti-IL-4 antibody at the start of the culture is 500 μng / mL or more, or 1 μg / mL or more in one or more embodiments. The upper limit of the abundance of the anti-IL-4 antibody is not particularly limited, and is an extent that does not inhibit differentiation induction into CD4-CD8αα + T cells, and in one or more embodiments, is 30 μg / mL or less.

[Other culture conditions]
In one or a plurality of embodiments, the culture temperature in the differentiation induction method according to the present disclosure is 35 to 39 ° C, 36 to 38 ° C, or 37 ° C. The culture medium is not particularly limited, and a conventionally known or later-developed medium that can be used for T cell culture can be used.

[Method for producing CD4-CD8αα + T cells]
In one or a plurality of embodiments, the present disclosure relates to a method for producing CD4-CD8αα + T cells, which includes performing the differentiation induction method according to the present disclosure. In one or a plurality of embodiments, the production method according to the present disclosure may include a step of separating or isolating CD4-CD8αα + T cells after the differentiation induction method. Alternatively, in one or a plurality of embodiments, the production method according to the present disclosure may be a cell population including CD4-CD8αα + T cells after the differentiation induction method. Therefore, in one or a plurality of embodiments, the present disclosure relates to a CD4-CD8αα + T cell produced by the production method according to the present disclosure, or a cell population containing a CD4-CD8αα + T cell.

[CD4-CD8αα + T cells / cell population]
The disclosure relates in one or more embodiments to CD4-CD8αα + T cells derived from CD4 + CD8- T cells, which are present in vitro. The present disclosure also relates to a cell population comprising CD4-CD8αα + T cells derived from CD4 + CD8- T cells, which are present in vitro in one or more embodiments. In one or a plurality of embodiments, Runx3 is expressed in CD4-CD8αα + T cells derived from CD4 + CD8- T cells according to the present disclosure.

In the present disclosure, “existing in vitro” means existing in vitro in one or a plurality of non-limiting embodiments, and differentiation-induced in vitro in one or more non-limiting embodiments. Say. In the present disclosure, “derived from CD4 + CD8- T cells” refers to cells generated from CD4 + CD8- T cells in one or more non-limiting embodiments, and is not limited to one or more embodiments. In CD4 + CD8- T cells.

The CD4-CD8αα + T cell derived from CD4 + CD8- T cell according to the present disclosure has, in one or more embodiments, a cell having an antigen receptor that easily becomes a CD4 T cell and having a cytotoxic T cell function. A group. In addition, since it has various TCRs derived from CD4 + T cells, it can exhibit various antigen specificities and may be able to cope with various immunosuppressive reactions. Furthermore, the CD4-CD8αα + T cells derived from CD4 + CD8- T cells according to the present disclosure can be said to be CD8 T cells activated without the help of other CD4T cells in one or a plurality of embodiments. Therefore, CD4-CD8αα + T cells derived from CD4 + CD8-T cells according to the present disclosure are, in one or more non-limiting embodiments, treated for autoimmune disease or improved antitumor effect, and antiviral It may be useful for improving the effect. Further, the CD4-CD8αα + T cells derived from CD4 + CD8- T cells according to the present disclosure may have a function as regulatory T cells in one or a plurality of embodiments as shown in Examples described later.

[Pharmaceutical composition and use thereof]
Accordingly, the present disclosure, in one or more embodiments, relates to a pharmaceutical composition comprising a CD4-CD8αα + T cell derived from a CD4 + CD8- T cell according to the present disclosure, or a cell population comprising the T cell. In one or a plurality of embodiments, the present disclosure is a pharmaceutical composition for preventing, ameliorating, suppressing progression, and / or treating an autoimmune disease, a malignant tumor, or a viral infection, The present invention relates to a pharmaceutical composition comprising a CD4 + CD8- T cell-derived CD4-CD8αα + T cell according to the disclosure or a cell population containing the T cell.

In one or a plurality of embodiments, the pharmaceutical composition according to the present disclosure is a pharmaceutically acceptable in addition to the CD4 + CD8-α T cell derived from the CD4 + CD8- T cell according to the present disclosure, or a cell population containing the T cell. Including possible carriers. In this disclosure, the term “pharmaceutically acceptable” is described in the Japanese Pharmacopoeia, the US Pharmacopoeia, the European Pharmacopoeia, or other generally accepted pharmacopoeia for use in animals and / or humans. Means that In this disclosure, the term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. The pharmaceutical composition can also contain small amounts of pH buffering agents, if desired. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by EW Martin. In one or a plurality of embodiments, the pharmaceutical composition according to the present disclosure is an effective amount of the cells or cells for prevention, amelioration, progression inhibition, and / or treatment of autoimmune disease, malignant tumor, or viral infection. Includes population.

The pharmaceutical composition according to the present disclosure can be in various forms. In one or more embodiments, the pharmaceutical composition according to the present disclosure includes a solid, semi-solid, or liquid dosage form, such as a lyophilized formulation, a liquid solution, a suspension, an injectable solution, or And liquid for infusion. The preferred form may vary depending on the intended mode of administration and therapeutic application. The method for administering the pharmaceutical composition according to the present disclosure to a subject can be performed by ordinary means. A pharmaceutical composition according to the present disclosure may be administered to a patient in one or more embodiments, as a graft, or by direct delivery to a desired tissue. The pharmaceutical composition according to the present disclosure can be transported to a desired tissue by any appropriate method. In one or more embodiments, the pharmaceutical composition is transported to a body part using a device such as a catheter, trocar, cannula, and stainless steel. can do.

In one or a plurality of embodiments, the present disclosure is a CD4 + CD8- T cell according to the present disclosure for prevention, amelioration, progression suppression, and / or treatment of an autoimmune disease, a malignant tumor, or a viral infection. The present invention relates to a CD4-CD8αα + T cell derived from or a cell population containing the T cell. In one or a plurality of embodiments, the present disclosure provides a pharmaceutical composition for preventing, ameliorating, suppressing progression, and / or treating an autoimmune disease, a malignant tumor, or a viral infection. The present invention relates to the use of CD4-CD8αα + T cells derived from CD4 + CD8- T cells according to the present disclosure, or a cell population containing the T cells. Furthermore, in one or a plurality of embodiments, the present disclosure is a method for preventing, ameliorating, suppressing progression, and / or treating an autoimmune disease, a malignant tumor, or a viral infection, and the CD4 according to the present disclosure. The present invention relates to a method comprising administering to a subject a CD4-CD8αα + T cell derived from + CD8- T cell, or a cell population containing the T cell. Examples of the administration subject of the pharmaceutical composition according to the present disclosure or the CD4 + CD8-α T cell-derived CD4-CD8αα + T cell according to the present disclosure or a cell population containing the T cell include animals other than humans or humans. .

[Screening method]
In one or a plurality of embodiments, the present disclosure relates to a screening method for a substance that promotes or suppresses differentiation induction from CD4 + CD8− T cells to CD4-CD8αα + T cells. In one or a plurality of embodiments, the screening method includes performing the differentiation induction method according to the present disclosure. In one or a plurality of other embodiments, the screening method includes performing a differentiation induction method according to the present disclosure, and selecting a candidate substance from a test substance using an effect of differentiation induction as an index.

In one or a plurality of embodiments, the present disclosure is a screening method for a candidate substance that promotes or suppresses differentiation induction in vivo from CD4 + CD8- T cells to CD4-CD8αα + T cells, comprising: Performing the differentiation induction method according to the present disclosure in the presence, and selecting a test substance that promotes or suppresses the differentiation induction efficiency of CD4-CD8αα + T cells as compared to the case in the absence of the test substance as a candidate substance The present invention relates to a screening method comprising

In one or a plurality of embodiments, the screening method according to the present disclosure may be aimed at selecting a “candidate substance” to be determined as a substance that promotes or suppresses differentiation induction through further examination. In one or a plurality of embodiments, the screening method according to the present disclosure may further include a step of further examining the selected candidate substance and determining a substance that promotes or suppresses differentiation induction.

[Test substance]
The test substance in the screening method according to the present disclosure is not particularly limited. In the present disclosure, the “substance” may be a compound, composition, mixture, extract, natural product, or synthetic product in one or more embodiments. In one or a plurality of embodiments, the test substance may use a screening library, and is not particularly limited. However, the test substance may be a compound or a salt thereof, a composition, a mixture, an extract, a natural product, or a synthetic product library. Available.

[kit]
In one or a plurality of embodiments, the present disclosure relates to a kit for performing the differentiation induction method according to the present disclosure or a kit for performing the screening method according to the present disclosure. In one or a plurality of embodiments, the kit according to the present disclosure includes a culture plate coated with a means for stimulating CD4 + CD8− T cells, IL-2, TGF-β1, atRA, and TCR, an anti-CD28 antibody, and an anti-IFN. -γ antibody, anti-IL-4 antibody, medium, and at least one selected from instructions of the differentiation induction method according to the present disclosure.

That is, the present disclosure may relate to one or more of the following embodiments;
[A1] Inducing differentiation of CD4-CD8αα T cells from CD4 + CD8- T cells, including in vitro culture of CD4 + CD8- T cells in the presence of IL-2, TGF-β1, and atRA how to;
[A2] The differentiation induction method according to [A1], wherein the CD4 + CD8− T cells are naive CD4 T cells;
[A3] The differentiation induction method according to [A1], wherein an antigen-specific CD4 + CD8- T cell or a cell population in which an antigen-specific CD4 + CD8- T cell is expanded is used as the CD4 + CD8- T cell;
[A4] The differentiation induction method according to any one of [A1] to [A3], wherein the culture is performed on a culture plate coated with a means for stimulating TCR;
[A5] The differentiation induction method according to any one of [A1] to [A4], wherein the culture is performed for 6 days or more;
[A6] The differentiation induction method according to any one of [A1] to [A5], wherein the number of CD4 + CD8− T cells at the start of culture is 5.0 × 10 ⁵ cells / mL or less;
[A7] The differentiation induction method according to any one of [A1] to [A6], wherein the concentration of atRA exceeds 1 μM;
[A8] The culture is further performed under conditions where one, two, or three types of antibodies selected from the group consisting of an anti-CD28 antibody, an anti-IFN-γ antibody, and an anti-IL-4 antibody are present. The differentiation induction method according to any one of [A1] to [A7];
[A9] A method for producing CD4-CD8αα + T cells, comprising performing the differentiation induction method according to any one of [A1] to [A8];
[A10] CD4-CD8αα + T cells produced by the differentiation induction method according to any one of [A1] to [A8];
[A11] CD4-CD8αα + T cells derived from CD4 + CD8- T cells existing in vitro;
[A12] a cell population containing CD4-CD8αα + T cells derived from CD4 + CD8- T cells existing in vitro;
[A13] The T cell of [A11], or the cell population of [A12], wherein Runx3 is expressed;
[A14] A pharmaceutical composition comprising the T cell or cell population according to any one of [A11] to [A13];
[A15] The pharmaceutical composition according to [A14] for the prevention, amelioration, progression inhibition, and / or treatment of autoimmune diseases, malignant tumors, or viral infections;
[A16] Use of the differentiation induction method according to any one of [A1] to [A8] in screening for a substance that promotes or suppresses differentiation induction from CD4 + CD8- T cells to CD4-CD8αα + T cells;
[A17] A screening method for a substance that promotes or suppresses in vivo differentiation induction from CD4 + CD8- T cells to CD4-CD8αα + T cells, in the presence of a test substance, from [A1] to [A8] Performing the differentiation inducing method according to any one of the above, and selecting a test substance that promotes or suppresses the differentiation induction efficiency of CD4-CD8αα + T cells as compared with the absence of the test substance as a candidate substance. Including a screening method;
[A18] A kit for performing the differentiation induction method according to any one of [A1] to [A8] or the screening method according to [A16] or [A17], comprising CD4 + CD8− T cells, IL-2 A kit comprising at least one selected from the group consisting of a culture plate coated with a means for stimulating TGF-β1, atRA and TCR.

Hereinafter, the present disclosure will be described in more detail by way of examples. However, these examples are illustrative, and the present disclosure is not limited to these examples.

[In vitro differentiation induction from naive CD4 T cells to CD4-CD8αα + T cells]
Naive CD4 T cells were isolated and prepared from C57BL / 6 spleen cells, and CD8αα T cells were induced to differentiate in vitro. In vitro differentiation induction conditions from naive CD4 T cells to CD4-CD8αα + T cells were as follows.

[In vitro differentiation inducing conditions from naive CD4 T cells to CD4-CD8αα + T cells]
Naive CD4 + TCRαβ + T cells were prepared from C57BL / 6 spleen cells using an appropriate kit for Magnetic Activated Cell Sorting (MACS) method. Naive CD4 T cells (1 x 10 ⁵ cells / mL) were mixed with anti-CD28 antibody (1 μg / mL), anti-IFN-γ antibody (3 μg / mL), anti-IL-4 antibody (3 μg / mL), TGF-β ( 3 ng / mL), IL-2 (20 ng / mL), and atRA (10 nM-10 μM) in the presence of anti-CD3 antibody-coated plate (5 μg / mL) for 7-9 days.

In the invitro differentiation induction conditions, IL-2, TGF-β1, and all-trans retinoic acid (hereinafter referred to as “atRA”) used for induction of iTreg (inducible regulatory T cells; CD4 + Foxp3 + regulatory T cells). All three elements are also required. On the other hand, atRA is not essential for iTreg induction, it is just a support element. The results of FACS analysis of cells induced to differentiate in vitro (FACSCaliburor®FACSAria, manufactured by Becton®Dickinson) are shown in FIG. 1a. As shown in FIG. 1a, CD4-CD8αα + T cells were induced to differentiate from naive CD4 T cells in vitro.

[In vitro differentiation induction from CD8αβ + T cells to CD8αα + T cells]
Induction treatment was performed in the same manner as the in vitro differentiation induction conditions employed in FIG. 1a except that CD8αβ + TCRαβ + T cells prepared in the same manner as naive CD4 T cells were used instead of naive CD4 T cells. The result of the FACS analysis (same as above) is shown in FIG. 1b. As shown in FIG. 1b, when CD8αβ + T cells were used, the generation of CD8αα + T cells was not observed.

[Interleukins used for induction of differentiation in vitro]
Interleukin (IL) plays an important role in the differentiation of helper T cell subsets. Therefore, naive CD4 T cells were stimulated under the in vitro differentiation induction conditions employed in FIG. 1a employing various ILs instead of IL2. The result of the FACS analysis (same as above) is shown in FIG. As shown in FIG. 1c, IL-2 had the strongest effect on CD8αα + T cell development.

[TCR signal intensity and atRA concentration in induction of differentiation in vitro]
TCR signal intensity (anti-CD3 antibody concentration), atRA concentration and induction efficiency in in vitro differentiation induction of CD8αα + T cells were examined. The result is shown in FIG. FIG. 1d shows that the in vitro differentiation induction efficiency of CD8αα + T cells was improved as TCR stimulation was stronger (more anti-CD3 antibody) and atRA concentration was higher.

[Gene expression pattern of differentiation induced CD4-CD8αα + T cells]
The gene expression of CD4-CD8αα + T cells differentiated in vitro was confirmed. Naive CD4 T cells were stimulated under the in vitro differentiation induction conditions employed in FIG. 1a, and the expression of various genes was evaluated by FACS analysis. An example of the result is shown in FIG. As shown in FIG. 2a, Granzyme A and B expression increased while Foxp3 expression decreased in the CD8αα population. In the CD8αα population, the expression of CD122 and ICOSL on the cell surface increased.

Next, naive CD4 T cells were stimulated under the above-described in vitro differentiation induction conditions employed in FIG. 1a, and CD4 + T cells and CD8 + 選別 T cells were selected, respectively, CD4 + T cells (iTreg), CD8 + T cells (CD8αα T cells), And gene expression in naive CD4 T cells was analyzed using RT-PCR. An example of the result is shown in FIG. As shown in FIG. 2b, Runx1 and ThPOK were specifically expressed in naive CD4 T cells. Moreover, after differentiation induction, the expression of Runx3 was confirmed in CD8αα T cells, but the expression of Runx3 was not confirmed in naive CD4 T cells and iTreg subsets.

[Confirmation of CD8αα + T cells in the spleen]
Lymphocytes were collected from the spleen of wild-type C57BL / 6 mice immunized by injecting 100 μg of NP-chicken gamma globulin (CGG) (in alum) into the peritoneal cavity, and CD8αα + CD8αβ-CD4-TCRαβ T The presence of cells was confirmed. The result is shown in FIG. As shown in FIG. 3, the proportion of CD8αα T cells in the spleen after immunization increased as compared to the unimmunized spleen.

[Confirmation that CD4-CD8αα + T cells develop in vivo from CD4 + TCRαβ T cells]
Naive CD4 T cells were isolated and prepared from C57BL / 6 spleen cells and transplanted into RAG2-deficient (Rag2-/-) mice (mice that cannot produce lymphocytes), and then evaluated whether they could be redifferentiated into CD8αα T cells in vivo. For transplantation, 0.5-2.5 × 10 ⁶ naive CD4 T cells (CD45.2) were used. FACS analysis was performed on lymphocytes of Rag2 − / − mice (CD45.1) 6 months after transplantation of naive CD4 T cells. The result is shown in FIG. Although CD8αα T cells could not be detected 20 days after the transplantation, the generation of CD8αα T cells was confirmed 6 months after the transplantation as shown in FIG. That is, it was confirmed that the transdifferentiation from naive CD4 T cells to CD4-CD8αα + T cells occurs in vivo as well as in vitro differentiation induction.

[Necessity of Runx3 for induction of differentiation in vitro]
Using naive CD4 T cells prepared from Runx3-deficient mice, it was confirmed whether CD4-CD8αα + T cells can be induced to differentiate in vitro. Naive CD4 T cells derived from wild-type or Runx3-/-fetal liver (FL) were stimulated under the in vitro differentiation-inducing conditions employed in FIG. 1a. The cell population after induction was analyzed by FACS. The result is shown in FIG. As shown in FIG. 5, Runx3-/-naive CD4 T cells were unable to undergo in vitro transdifferentiation into CD4-CD8αα + T cells.

[Necessity of Runx3 for transdifferentiation in vivo]
Naive CD4 T cells were isolated and prepared from Runx3-deficient mice, transplanted to RAG2-deficient (Rag2-/-) mice (mouse that cannot produce lymphocytes), and then evaluated whether they could be transformed into CD4-CD8αα + T cells in vivo. . 0.5-2.5 × 10 ⁶ naive CD4 T cells (CD45.2) derived from wild-type or Runx3-/-fetal liver (FL) were transplanted into Rag2-/-mice (CD45.1). 200 μg / 100 μL atRA dissolved in soybean oil was injected into the abdominal cavity for immunization, and 6 days later, lymphocytes were collected and FACS analysis was performed. The results of spleen, Peyer's patch (PP), small intestine and large intestine intraepithelial lymphocytes (IEL), and small intestine and large intestine lamina propria (LPL) lymphocytes are shown in FIG.

As shown in FIG. 6, atRA-dependent in vivo transdifferentiation from wild type naive CD4 T cells to CD4-CD8αα + T cells occurred in peripheral lymphoid tissues. On the other hand, atRA-dependent in vivo transdifferentiation did not occur in Runx3-deficient naive CD4 T cells. Therefore, it was confirmed that Runx3 plays an extremely important role in transdifferentiation from naive CD4 T cells to CD4-CD8αα + T cells.

[Timing of in vivo transdifferentiation]
Naive CD4 T cells (CD45.2) were isolated and prepared from C57BL / 6 spleen cells, transplanted to RAG2-deficient (Rag2-/-) mice (CD45.1) in the same manner as above, and then dissolved in soybean oil at 200μg / 100μL Of atRA was injected into the peritoneal cavity for immunization, and lymphocytes (CD45.2) were collected 1, 3, and 6 days after the immunization, and FACS analysis was performed. The results are shown in FIGS. 7a and b. As shown in FIG. 7a, approximately 1% of CD8αα T cells were detected after 1, 3, and 6 days in the spleen. This value is a value during normal immunization. As shown in FIG. 7b, a significantly larger CD4-CD8αα + T cell population was confirmed in the Peyer's patch, IEL, and LPL after 6 days compared to after 1 and 3 days. These results suggest that transdifferentiation from naive CD4 T cells to CD4-CD8αα + T cells occurs at the site of immune response, and that newly generated CD4-CD8αα + T cells migrate to the intestine.

[Functions as regulatory T cells]
In a multiple sclerosis mouse disease model (experimental autoimmune encephalitis (EAE)), Runx3-deficient mice and wild-type mice were compared. EAE is known that CD8T cells are important for suppression of disease states. Therefore, this autoimmune disease model is suitable for examining the function of CD4-CD8αα + T cells as regulatory T cells.

Specifically, Rag2-/-mice were injected with wild-type or Runx3-/-lymphocytes and followed up for signs of neurological disease after inducing EAE. The result is shown in FIG. 8a. As shown in FIG. 8a, there was no difference between the two genotypes in the EAE clinical score and EAE prevalence immediately after the start of the experiment. However, Runx3-/-mice failed to recover from EAE, and there was a significant difference in the EAE clinical score after 6 weeks (P 週 = 0.0010). These data indicate that CD4-CD8αα + T cells play an important regulatory role, i.e., a regulatory T cell, in the negative feedback loop that reduces negative effects during the immune response. Suggest (see Figure 8b).

Claims

A method for inducing differentiation of CD4-CD8αα- T cells from CD4 + CD8- T cells, comprising incubating CD4 + CD8- T cells in vitro in the presence of IL-2, TGF-β1, and atRA.
The method for inducing differentiation according to claim 1, wherein the CD4 + CD8- T cells are naive CD4 T cells.
The differentiation inducing method according to claim 1, wherein an antigen-specific CD4 + CD8- T cell or a cell population in which an antigen-specific CD4 + CD8- T cell is expanded is used as the CD4 + CD8- T cell.
The differentiation induction method according to any one of claims 1 to 3, wherein the culture is performed on a culture plate coated with a means for stimulating TCR.
The differentiation induction method according to any one of claims 1 to 4, wherein the culture is performed for 6 days or more.
6. The differentiation induction method according to claim 1, wherein the number of CD4 + CD8− T cells at the start of culture is 5.0 × 10 5 cells / mL or less.
The differentiation induction method according to any one of claims 1 to 6, wherein the concentration of atRA at the start of culture exceeds 1 µM.
The culture is further performed under conditions in which one, two, or three types of antibodies selected from the group consisting of an anti-CD28 antibody, an anti-IFN-γ antibody, and an anti-IL-4 antibody are present. Item 8. The differentiation induction method according to any one of Items 1 to 7.
A method for producing CD4-CD8αα + T cells, comprising performing the differentiation induction method according to any one of claims 1 to 8.
CD4-CD8αα + T cells produced by the differentiation induction method according to any one of claims 1 to 8.
CD4-CD8αα + T cells derived from CD4 + CD8- T cells, existing in vitro.
A cell population containing CD4-CD8αα + T cells derived from CD4 + CD8- T cells, existing in vitro.
The T cell according to claim 11 or the cell population according to claim 12, wherein Runx3 is expressed.
A pharmaceutical composition comprising the T cell or cell population according to any one of claims 11 to 13.
The pharmaceutical composition according to claim 14, for the prevention, improvement, progression inhibition and / or treatment of autoimmune disease, malignant tumor or viral infection.
Use of the differentiation inducing method according to any one of claims 1 to 8 in screening for a substance that promotes or suppresses differentiation induction from CD4 + CD8- T cells to CD4-CD8αα + T cells.
9. A screening method for a substance that promotes or suppresses in vivo differentiation induction from CD4 + CD8- T cells to CD4-CD8αα + T cells, wherein the method is any one of claims 1 to 8 in the presence of a test substance. And a method for selecting a test substance that promotes or suppresses the differentiation induction efficiency of CD4-CD8αα + T cells as compared with the absence of the test substance as a candidate substance.
A kit for performing the differentiation inducing method according to any one of claims 1 to 8 or the screening method according to claim 16 or 17, comprising CD4 + CD8- T cells, IL-2, TGF-β1, atRA And at least one selected from the group consisting of culture plates coated with means for stimulating TCR.